Streetbeat News

AMLX

Amylyx Pharmaceuticals, Inc.

Industry

Biotechnology

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Open

3.59

Mkt cap

332M

Volume

409K

High

3.82

P/E Ratio

-0.85

52-wk high

7.27

Low

3.57

Div yield

N/A

52-wk low

1.57

The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a negative opinion on Amylyx Pharmaceuticals' conditional marketing authorization of AMX0035 for amyotrophic lateral sclerosis (ALS). This contradicts positive approvals from the FDA and Health Canada. Amylyx plans to request a formal re-examination of the Marketing Authorization Application procedure.

Portfolio Pulse from Vandana Singh

June 23, 2023 | 1:27 pm

Amylyx Pharmaceuticals' shares are trading lower after the EMA's CHMP adopted a negative opinion on the application for conditional marketing authorization of AMX0035 for amyotrophic lateral sclerosis.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 12:21 pm

Amylyx Pharmaceuticals received a negative opinion from the CHMP on its conditional marketing authorization application for AMX0035, a treatment for ALS in the EU. The company plans to seek re-examination of its application.

Portfolio Pulse from Bill Haddad

June 23, 2023 | 12:15 pm

Amylyx Pharmaceuticals (NASDAQ: AMLX) has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the reimbursement of ALBRIOZA, a treatment for amyotrophic lateral sclerosis (ALS). The company will now work with federal, provincial, and territorial drug plans to ensure public coverage for eligible Canadians with ALS.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 1:15 pm

Amylyx Pharma (NASDAQ:AMLX) has received 6 bullish and 1 indifferent analyst ratings in the last quarter, with an average 12-month price target of $50.43, up 5.06% from the previous average of $48.00.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 1:02 pm

HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Amylyx Pharma (NASDAQ:AMLX) and maintained a $50 price target.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 10:46 am

Amylyx Pharmaceuticals has been informed that the CHMP is trending toward a negative opinion on the application for conditional marketing authorization for AMX0035, a treatment for ALS.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 12:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.